trending Market Intelligence /marketintelligence/en/news-insights/trending/4JH_ohD3YsJKKzPmNsCrYg2 content esgSubNav
In This List

Strongbridge Biopharma closes share offering

Blog

Insight Weekly: M&A players predict 2023 activity; SPAC IPOs dip; 2022 capacity retirements up

Blog

Insight Weekly: Recession risk persists; Banks pull back from crypto; 2022 laggard stocks rally

Blog

Highlighting the Top Regional Aftermarket Research Brokers by Sector Coverage

Blog

Insight Weekly: Inflation eases; bank M&A slows; top companies boost market share


Strongbridge Biopharma closes share offering

Strongbridge Biopharma plc closed its underwritten public offering of 4 million shares for net proceeds of about $23.4 million.

The company plans to use net proceeds to advance its drug pipeline, including Keveyis to treat primary periodic paralysis and Recorlev to treat Cushing's syndrome, and for other general corporate purposes and general and administrative expenses.

Cantor Fitzgerald & Co. acted as the sole book-running manager and Oppenheimer & Co. Inc. and H.C. Wainwright & Co. LLC acted as co-managers for the offering.